| Literature DB >> 20126383 |
Rashida A Ferrand1, Tsitsi Bandason, Praise Musvaire, Natasha Larke, Kusum Nathoo, Hilda Mujuru, Chiratidzo E Ndhlovu, Shungu Munyati, Frances M Cowan, Diana M Gibb, Elizabeth L Corbett.
Abstract
BACKGROUND: Survival to older childhood with untreated, vertically acquired HIV infection, which was previously considered extremely unusual, is increasingly well described. However, the overall impact on adolescent health in settings with high HIV seroprevalence has not previously been investigated. METHODS ANDEntities:
Mesh:
Year: 2010 PMID: 20126383 PMCID: PMC2814826 DOI: 10.1371/journal.pmed.1000178
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Figure 1Study recruitment procedure for eligible participants.
Baseline demographic, clinical, and growth characteristics of adolescents admitted to hospital (n = 301 unless specified otherwise).
| Characteristic |
|
| |
| HIV-Infected, | HIV-Negative, | ||
|
| |||
| Median age y (IQR) | 13 (11–15) | 13 (11–16) | 0.14 |
| Female | 65 (47) | 65 (40) | 0.25 |
| Orphan (single or double) | 111 (80) | 58 (36) | <0.001 |
| Mother dead or known to be HIV-infected | 101 (73) | 28 (17) | <0.001 |
| Married | 1(1) | 8 (5) | 0.032 |
| Currently attending school | 97 (70) | 116 (72) | 0.73 |
| Previously tested for HIV | 103 (74) | 20 (12) | <0.001 |
| HIV status already known by patient | 86 (62) | 20 (12) | <0.001 |
|
| |||
| Previous TB treatment | 61 (44) | 3 (2) | <0.001 |
| Previously hospitalised more than once ( | 39 (29) | 21 (13) | <0.001 |
| WHO HIV clinical stage 3/4 | 115 (83) | — | — |
| Receiving antiretroviral therapy | 45 (32) | — | — |
| Self-rated general health “fair” or “poor” | 120 (86) | 49 (30) | <0.001 |
| Poor performance scores (WHO scale 3/4) | 64 (46) | 20 (12) | <0.001 |
| Median CD4+ count, cells/µl (IQR) ( | 151 (57–328) | — | — |
|
| |||
| Weight-for-age | 88 (72) | 29 (20) | <0.001 |
| Height-for-age | 63 (52) | 32 (23) | <0.001 |
| Body mass index | 74 (73) | 28 (27) | <0.001 |
| Median mid-upper arm circumference, mm (IQR) ( | 172.5 (147–190.5) | 204.5 (180–231) | <0.001 |
| Tanner's stage 1/2 (those ≥14 y) | 21 (15) | 4 (2) | <0.001 |
| Occurrence of menarche (females only) | 18 (28) | 34 (52) | 0.005 |
| Self-reported consensual sexual debut ( | 6 (9) | 18 (22) | 0.031 |
| Self-reported forced sexual intercourse ( | 5 (8) | 4 (5) | 0.46 |
Data reported as percentage of patients and Chi-squared test used to compare HIV-infected and HIV-negative participants unless specified otherwise.
Data reported as median, not as percentage of patients and Mann Whitney U test used for comparison of medians between HIV-infected and HIV-negative participants.
HIV-infected participants: 14 living mothers HIV-infected; HIV-negative participants: five living mothers HIV-infected.
20 patients previously tested but HIV result not disclosed to patient.
Scale 3, bedridden, <50% of the day during the last month; scale 4, bedridden, >50% of the day during the last month.
Data missing for 14 patients: six deaths before sample taken, one unable to venesect (severe wasting), seven inadequate volumes.
Data missing for 35 patients due to inability to stand: 20 too ill, eight fractured lower limb, four chronic disability, three pathology in lower limb (two joint infection/one soft tissue infection).
Data missing for 38 patients: 35 as for b, plus two unable to stand upright, one acute confusion.
Data not available for151 patients (72 patients HIV-infected, 79 patients HIV-negative): 88 patients under 12 y, 63 patients too ill.
Data missing for 154 patients: 151 as for f, three patients question not answered (two HIV-negative and one HIV-infected).
Causes of admission among adolescents admitted to hospital.
| Cause of Admission (Up to Four Causes Allowed) | Condition |
|
| |
| HIV-Infected, | HIV-Negative, | |||
|
| 96 (69) | 30 (19) | <0.001 | |
|
| Any mycobacterial disease | 25 (18) | 3 (2) | — |
| Tuberculosis | 24 | 3 | — | |
|
| 1 | 0 | — | |
|
| Any bacterial infection | 65 (47) | 20 (12) | — |
| Acute pneumonia | 24 | 1 | — | |
| Bronchitis | 9 | 2 | — | |
| Meningitis | 9 | 2 | — | |
| Soft tissue or bone/joint infection | 2 | 5 | — | |
| Enteritis | 5 | 3 | — | |
| Urinary tract infection | 1 | 1 | — | |
| ENT infection | 0 | 2 | — | |
| Sexually transmitted infection | 1 | 1 | — | |
| Blood stream infection | 12 | 1 | — | |
| Organ abscess | 2 | 2 | — | |
|
| Any fungal infection | 35 (25) | 0 (0) | — |
| Cryptococcosis | 15 | 0 | — | |
| Oesophageal candidiasis | 21 | 0 | — | |
| PCP | 1 | 0 | — | |
|
| Any other infection | 8 (6) | 10 (6) | — |
| Malaria | 2 | 5 | — | |
| Viral | 3 | 3 | — | |
| Other | 3 | 2 | — | |
|
| 15 (11) | — | — | |
|
| 4 (3) | 53 (33) | <0.001 | |
| Road-traffic accident | 0 | 19 | — | |
| Assault | 1 | 4 | — | |
| Accident in the home | 3 | 30 | — | |
| Complications of previous trauma | 1 | 6 | — | |
|
| 1 (0.7) | 18 (11) | <0.001 | |
|
| 2 (1.4) | 15 (9) | 0.003 | |
|
| 53 (48) | 52 (38) | 0.080 | |
| Stroke | 4 | 0 | — | |
| Cardiac failure | 9 | 12 | — | |
| Exacerbation of chronic condition other than cardiac/respiratory | 1 | 16 | — | |
| Malignancy | 8 | 6 | — | |
| Severe anaemia (Hb<7g/dl) | 34 | 14 | — | |
| Drug toxicity | 4 | 0 | — | |
| Malnutrition | 3 | 1 | — | |
| Other | 4 | 12 | — | |
Data indicate the numbers and percentages of patients with ≥1 diagnosis in that category.
HIV-infected: pulmonary, 12 (five smear-positive, one culture-positive only, six radiological); blood culture-positive, 4; TB meningitis, 2 (one with concurrent disseminated lymphadenopathy); unilateral pleural effusion, 3; arthritis confirmed on synovial biopsy, 1; miliary shadowing, 1; abdominal para-aortic lymphadenopathy confirmed on fine needle aspirate, 1; HIV-negative: pulmonary, 1 (smear-positive); blood culture-positive, 1; pericardial effusion, 1.
HIV-infected: nontyphoidal Salmonella spp, 1; Staphylococcus aureus, 2; lactose-fermenting coliforms, 1; nonlactose-fermenting coliforms (except Salmonella spp), 1; Group D Streptococcus, 1; HIV-negative: S. aureus, 1.
HIV-infected: empyema, 2; HIV-negative: intracranial abscess, 2.
HIV-infected: scabies, 2; self-limiting fever, 1; HIV-negative: rheumatic fever, 1, self-limiting fever, 1.
Stevens Johnsons syndrome secondary to cotrimoxazole, 2; hepatitis secondary to nevirapine, 1; lactic acidosis secondary to stavudine, 1.
HIV-infected: anal fissures, 1; renal condition (one renal failure and one glomerulonephritis), 2; deep vein thrombosis, 1; HIV-negative: renal condition (two glomerulonephritis and three nephrotic syndrome), 5; dysfunctional uterine bleeding, 3; gastritis, 2; hepatitis, 1; pellagra, 1.
ENT, ear, nose, and throat; PCP, pneumocystis pneumonia.
Chronic conditions among adolescents admitted to hospital.
| Chronic Condition |
|
| |
| HIV-Infected, | HIV-Negative, | ||
| Chronic lung disease | 17 (12) | 0 (0) | <0.001 |
| Cardiac disease | 9 (6) | 12(7) | 0.72 |
| Rheumatic heart disease | 0 | 9 | — |
| Cor-pulmonale | 0 | 0 | — |
| Dilated cardiomyopathy | 9 | 1 | — |
| Other | 1 | 2 | — |
| Diabetes | 0 (0) | 7 (4) | 0.017 |
| Epilepsy | 0 (0) | 3 (2) | 0.093 |
| Asthma | 0 (0) | 4 (2) | 0.093 |
| Chronic skin disease | 97 (70) | 11 (7) | <0.001 |
| Other chronic | 23 (17) | 25 (15) | 0.63 |
| Neurological | 7 | 2 | — |
| Malignancy | 8 | 6 | — |
| Haematological | 1 | 3 | — |
| Chronic infection/inflammation | 1 | 5 | — |
| Blindness | 4 | 0 | — |
| Polyarthritis | 1 | 2 | — |
| Congenital | 1 | 7 | — |
Static radiological appearance of focal scarring, and/or opacification, and/or cystic changes, and/or bronchial wall thickening, plus negative TB smears and cultures from current episode, plus ≥2 of the following: clubbing, recurrent (at least two) episodes of cough productive of copious amounts of purulent sputum in the last 3 mo, persistent fine basal crepitations, and/or wheezes on auscultation, cor pulmonale.
Meets above case definition for chronic lung disease plus echocardiographic finding of right ventricular enlargement or ≥2 of the following: ascites, hepatomegaly, raised jugular venous pressure, ankle oedema.
HIV-infected: 4, Kaposi Sarcoma; 2, Non-Hodgkins's lymphoma; 1, osteogenic sarcoma; 1, cholangiocarcinoma. HIV-negative: 3, haematological malignancy; 2, intracranial tumours; 1, myxoid neurofibroma.
Causes of death among adolescents admitted to hospital.
| Cause of Death |
|
| |
| HIV-Infected ( | HIV-Negative ( | ||
| Tuberculosis | 4 (13) | 1 (9) | 5/27 (19) |
| Pneumonia | 3 (9) | 1 (9) | 4/25 (16) |
| Meningitis | 2 (6) | 1 (9) | 3/11 (27) |
| Bloodstream infection | 2 (6) | 0 | 2/13 (15) |
| Other infection | 1 (3) | 1 (9) | 2/11 (18) |
| Cryptococcosis | 6 (19) | 0 | 6/15 (40) |
| HIV wasting syndrome | 8 (25) | 0 | 8/15 (53) |
| Drug toxicity | 2 (6) | 0 | 2/4 (50) |
| Malignancy | 4 (13) | 5 (46) | 9/14 (64) |
| Cardiac failure | 0 | 2 (18) | 2/21 (10) |
The median time to death was 12 d (IQR 4–21 d) in HIV-infected and 10 d (IQR 6–20 d) in HIV-negative participants.
HIV-infected, empyema; HIV-negative, osteomyelitis.
Risk factors for death among adolescents admitted to hospital (n = 301 unless specified).
| Variable |
| Univariate OR (95% CI) |
| Final Multivariate OR |
|
|
| |||||
| Age | |||||
| 15–18 y | 5/84 (6) | 1.0 | 1.0 | ||
| 12 to <15 y | 27/129 (21) | 4.2 (1.5–11.4) | 0.005 | 2.5 (0.8–7.4) | 0.11 |
| <12 y | 11/88 (13) | 2.3 (0.7–6.8) | 0.15 | 2.0 (0.6–7.0) | 0.25 |
|
| |||||
| Biological parent | 12/126 (10) | 1.0 | 1.0 | ||
| Not biological parent | 31/175 (18) | 2.0 (1.0–4.2) | 0.05 | 1.3 (0.5–2.9) | 0.60 |
|
| |||||
|
| |||||
| HIV-negative | 11/162 (7) | 1.0 | — | 1.0 | — |
| HIV-infected and stage 1/2 | 2/24 (8) | 1.2 (0.3–5.7) | 0.85 | 1.0 (0.2–5.7) | 0.99 |
| HIV-infected and stage 3 | 5/36 (14) | 1.6 (0.5–5.1) | 0.42 | 1.6 (0.5–5.4) | 0.49 |
| HIV-infected and stage 4 | 25/79 (32) | 5.1 (2.3–11.4) | 0.0001 | 2.8 (1.1–7.1) | 0.03 |
|
| |||||
| Yes | 25/237 (11) | 1.0 | — | 1.0 | — |
| No | 18/64 (28) | 2.4 (1.2–4.9) | 0.02 | 1.3 (0.6–3.2) | 0.53 |
|
| |||||
| No | 12/217 (6) | 1.0 | — | 1.0 | — |
| Yes | 31/84 (37) | 8.2 (3.9–17.3) | 0.0001 | 6.9 (3.0–15.8) | 0.0001 |
|
| |||||
| No | 8/132 (6) | 1.0 | — | 1.0 | — |
| Yes | 35/169 (21) | 3.0 (1.3–6.9) | 0.01 | 0.4 (0.1–1.5) | 0.19 |
|
| |||||
| No | 34/276 (12) | 1.0 | — | 1.0 | — |
| Yes | 9/25 (36) | 3.1 (1.2–8.1) | 0.021 | 4.0 (1.4–11.6) | 0.01 |
|
| |||||
| No | 11/168 (7) | 1.0 | — | 1.0 | — |
| Yes | 17/95 (18) | 3.1 (1.3–7.3) | 0.01 | 1.2 (0.5–3.2) | 0.69 |
|
| |||||
| No | 6/149 (4) | 1.0 | — | 1.0 | — |
| Yes | 23/117 (20) | 5.2 (2.0–13.7) | 0.001 | 2.1 (0.6–6.9) | 0.23 |
|
| |||||
| No | 22/217 (10) | 1.0 | — | 1.0 | — |
| Yes | 21/84 (25) | 2.7 (1.3–5.3) | 0.005 | 2.8 (1.3–6.0) | 0.009 |
|
| |||||
| >11g/dl | 12/124 (10) | 1.0 | — | 1.0 | — |
| 7.0–10.9 g/dl | 13/110 (12) | 1.0 (0.4–2.4) | 0.97 | 0.4 (0.1–1.1) | 0.07 |
| <7.0 g/dl | 14/48 (29) | 3.6 (1.5–8.7) | 0.005 | 0.8 (0.3–2.5) | 0.72 |
Adjusted for age group and type of primary caregiver.
Adjusted for HIV stage, chronic disease, pubertal delay, and performance score.